Hypertension is associated with an increased risk of stroke, myocardial infarction and congestive heart failure. Hydralazine is a direct-acting vasodilator which has been used for the treatment of hypertension since the 1950's. Although it has largely been replaced by newer antihypertensive drugs with more acceptable tolerability profiles, hydralazine is still widely used in developing countries due to its lower cost. A review of its relative effectiveness compared to placebo on surrogate and clinical outcomes is justified.
Kandler, M. R., Mah, G. T., Tejani, A. M., Stabler, S. N., & Salzwedel, D. M. (2011). Hydralazine for essential hypertension. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.cd004934.pub4